# CAbotégravir LENacapavir DUal Long Acting

> **NCT06657885** · PHASE2 · WITHDRAWN · sponsor: **Institut de Médecine et d'Epidémiologie Appliquée - Fondation Internationale Léon M'Ba**

## Conditions studied

- HIV1 Infection
- Multi-treated Patients Who Have Received Multiple Lines of Antiretroviral Treatment
- CABOTEGRAVIR
- LENACAPAVIR
- Stable Oral Antiretroviral Treatment for at Least 6 Months

## Interventions

- **DRUG:** his is a prospective, single-arm, multicentre, non-randomised phase II, pilot study designed to achieve or maintain virological success in participants who meet the prescribing criteria for lenacapavi

## Key facts

- **NCT ID:** NCT06657885
- **Lead sponsor:** Institut de Médecine et d'Epidémiologie Appliquée - Fondation Internationale Léon M'Ba
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** WITHDRAWN
- **Start date:** 2025-01-15
- **Primary completion:** 2026-07-15
- **Final completion:** 2026-09-15
- **Target enrollment:** 0 (ACTUAL)
- **Why stopped:** No response regarding coverage of treatments by social security and the DGOS
- **Last updated:** 2026-01-14

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06657885

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06657885, "CAbotégravir LENacapavir DUal Long Acting". Retrieved via AI Analytics 2026-09-01 from https://api.ai-analytics.org/clinical/NCT06657885. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*